Search

Acupath LABORATORIES INC., Biomarkers, Bladder Cancer, Business, Cancer, Cancer Biomarkers, Carcinoma Biomarkers, Cytology, Diagnostics and Screening, Health and Medicine, Oncology, Risk and Prevention Keywords: Acupath LABORATORIES INC.; Biomarkers; Bladder Cancer; Business; Cancer; Cancer Biomarkers; Carcinoma Biomarkers; Cytology; Diagnostics and Screening; Health and Medicine; Oncology; Risk and Prevention EN Acupath LABORATORIES INC. Biomarkers Bladder Cancer Business Cancer Cancer Biomarkers Carcinoma Biomarkers Cytology Diagnostics and Screening Health and Medicine Oncology Risk and Prevention 69 69 1 09/19/23 20230919 NES 230919 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Acupath Labs released a white paper highlighting the impressive results of a large-scale internal study analyzing the clinical utility of its Acu-UR017 bladder cancer biomarker. [Extracted from the article]

A new editorial paper published in Oncotarget discusses acute myeloid leukemia (AML), a type of aggressive cancer. The paper highlights recent advancements in understanding AML biology and the potential for developing novel drug therapies. The researchers suggest exploring reductive carboxylation as a possible drug target to weaken tumor cell survival mechanisms and improve patient outcomes. The paper provides further information on this topic and can be accessed through the provided DOI link. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the therapeutic potential and challenges of cytostatic persister cancer cells. These cells are able to remain viable despite treatment and can contribute to residual diseases and the emergence of resistant clones and relapses. Unlike resistant cells, persister cancer cells enter a non-proliferating state that is reversible upon treatment discontinuation. The paper highlights the need to understand the properties of cytostatic persisters and explores strategies for targeting them to reduce cancer recurrence. The researchers suggest that administering multiple targeted regimens may be necessary to effectively deplete the persister reservoirs in patients undergoing cancer treatments. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the molecular functions of regulatory genetic variants associated with cancer. The paper highlights the challenges in understanding the effects of genetic variants, such as their small effect size and their location in non-protein-coding regions of the genome. The researchers propose integrating genomic, epigenomic, transcriptomic, and machine learning methods to identify functional genetic variants and characterize their mode of action in regulating target genes. This approach has implications for cancer research and precision medicine. [Extracted from the article]

A research paper published in Oncotarget's Volume 15 discusses the differential expression of the Mad2 gene in human esophageal cancer. The study focuses on the relationship between the consumption of raw areca nut and the development of esophageal squamous cell carcinoma (ESCC). The researchers found that Mad2 expression levels were both overexpressed and underexpressed in the samples, leading to premature anaphase and chromosome missegregation. The study suggests that Mad2 expression levels, along with chromosomal abnormalities, could serve as a clinical biomarker for esophageal cancer. Further research is needed to understand the role of the pRb-E2F1 circuit in Mad2 down-regulation. [Extracted from the article]